Why the study?
The study evaluated the capability of viscoelastic measurement parameters to screen the anticoagulation activity of edoxaban in relation to its plasma concentrations.
Does ROTEM viscoelastic testing correlate with edoxaban plasma concentrations in healthy volunteers?
Does ROTEM viscoelastic testing correlate with edoxaban plasma concentrations in healthy volunteers?
ROTEM clotting time correlates significantly with edoxaban plasma concentrations and may be used as a readily available on-site test to estimate the drug's anticoagulant effect.
Answers are grounded in this paper and cite their sources.
May support point-of-care edoxaban monitoring; hypothesis-generating in volunteers and requires patient validation.
The capability of viscoelastic measurement parameters to screen anticoagulation activity of edoxaban in relation to its plasma concentrations was evaluated in 15 healthy male volunteers. Blood samples were drawn before the oral administration of edoxaban 60 mg and 2, 4, 6, 8, and 24 hours after administration. At each time, standard coagulation tests were performed, blood viscoelastic properties were measured with a thromboelastometry device ROTEM delta analyzer (Instrumentation Laboratory, Werfen, Barcelona, Spain), and edoxaban plasma concentrations were measured. Our primary interest was the possible correlation between edoxaban plasma concentrations and values for ROTEM ExTEM, and FibTEM. We also studied the correlation of edoxaban plasma concentrations with the results of standard coagulation tests. We saw the effect of a single dose of edoxaban most clearly in clotting time (CT) of ROTEM ExTEM and FibTEM. Changes in these parameters correlated significantly with edoxaban plasma concentrations up to 6 hours from the ingestion of the drug. Activated partial thromboplastin time, prothrombin time, and anti-factor Xa were also affected. Peak changes were observed 2 and 4 hours after administration of edoxaban. The changes were mostly reversed after 8 hours. In conclusion, ROTEM CT correlates significantly with edoxaban plasma concentrations and can be used to estimate the effect of edoxaban. ROTEM should be considered as part of the assessment of coagulation, with the big advantage of being readily available on site.
No takes yet. Share an insight, caveat, or question.
Havrdová et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: